FDA issues Complete Response Letter to AbbVie’s trenibotulinumtoxinE, delaying a potential first-in-class aesthetic neurotoxin over manufacturing questions despite no identified safety or efficacy concerns.
AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for trenibotulinumtoxinE.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The drug is a first-in-class botulinum neurotoxin serotype E designed for facial aesthetics and the CRL sets back what the company positioned as a potentially transformative addition to the aesthetic toxin market.
The CRL, which the FDA issues when it cannot approve an application in its current form, cited a request for additional information about manufacturing processes.1 Critically, the letter did not identify any safety or efficacy concerns and did not request additional clinical studies, a distinction AbbVie was quick to emphasize.
The company says it is confident it can address the FDA's comments promptly and expects to submit a thorough response in the coming months. Regulatory reviews in other countries are continuing as expected.1
"We strongly believe trenibotulinumtoxinE is an important innovation in botulinum toxin science, with the potential to expand options for patients interested in facial aesthetics," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer at AbbVie. "Though disappointed, we remain confident in the strength and integrity of our application, and we are well positioned to respond to the agency's feedback promptly to support completion of the review."
TrenibotE is the first botulinum neurotoxin serotype E to be submitted for FDA approval, distinguishing it from existing neurotoxins including AbbVie's own Botox Cosmetic, which uses serotype A. Its key differentiator is a combination of rapid onset, with effects observed as early as eight hours after administration, the earliest assessment time in its clinical program, and a short duration of effect of two to three weeks. Existing botulinum toxin treatments typically last three to four months.1
AbbVie has positioned TrenibotE specifically for patients who have been reluctant to try neurotoxin treatments, citing research showing that fear of looking unnatural is a significant barrier for first-time patients.2 A shorter duration product could allow hesitant patients to try the treatment knowing the effects will resolve quickly, potentially serving as an entry point before committing to longer-lasting options.
The BLA was supported by data from more than 2,100 patients treated across two pivotal Phase III studies evaluating TrenibotE for moderate to severe glabellar lines and a Phase III open-label safety study. 2
All primary and secondary endpoints were met across the pivotal studies. Treatment-emergent adverse events were similar to placebo, both as a single treatment and across up to three consecutive treatments.
"Concern about an unnatural outcome remains a significant barrier for many patients considering medical aesthetics treatment," said Cheryl Burgess, MD, FAAD, lead clinical investigator for one of the Phase III studies. "Treatment with a product offering rapid onset of effect and short duration of action could help address this barrier and empower confidence for patients exploring their aesthetics treatment journey with innovation from the makers of Botox Cosmetic."
Darin Messina, Ph.D., senior vice president of aesthetics R&D at AbbVie, said at the time of the original BLA submission that TrenibotE has the potential to transform the aesthetic toxin treatment landscape for new patients.2
The manufacturing-related CRL delays but does not derail that ambition, with AbbVie signaling that it expects to resolve the outstanding questions without the need for new clinical work.
